Shares of DexCom Inc. DXCM slid 1.37% to $87.53 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.65% to ...

Shares of DexCom Inc. DXCM rose 2.30% to $86.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and the ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent ...

Continuous glucose monitoring (CGM) devices provide real-time blood sugar readings 24 hours a day, allowing people with type 1 or type 2 diabetes to closely track blood glucose levels and trends. Most ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Portfolio management is how you set yourself up for long-term financial success and stability. Learn how to square your own investments with your time horizon and risk tolerance. There’s no one ...